

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No.07-894-US-DIV)**

In re Application of:)	
)	
Cohen, Edward P.)	Group Art Unit: 1643
)	
Serial No. 09/522,716)	Examiner: Christopher H. Yaen
)	
Filed: March 10, 2000)	Confirmation No.: 6035
)	
For: Cancer Immunotherapy with Semi-Allogeneic)	
Cells)	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the references cited below are enclosed. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

U.S. Patent Documents

1. 6,022,538	Santoli et al.	Issued: February 8, 2000
2. 6,805,869	Guo	Issued: October 19, 2004
3. 7,060,802	Trakht et al.	Issued: June 13, 2006
4. 2002/0058041	Belldegrun et al.	Publication Date: May 16, 2002

Foreign Patent Documents

- | | | |
|-------------|----|----------------------------------|
| 5. 98/11202 | WO | Publication Date: March 19, 1998 |
| 6. 93/07906 | WO | Publication Date: April 29, 1993 |

Other Documents

7. Marshall, Science, 269:1050-1055, 1995.
8. Miller et al., FASEB J., 9:190-199, 1995.
9. Culver et al., TIG, 10(5): 174-179, 1994.
10. Blankenstein, T. et al., Tumor Suppression after Tumor Cell-targeted Tumor Necrosis Factor α Gene Transfer, J. Exp. Med., 173: 1047-1052 (1991).
11. Colombu, M. et al., Granulocyte Colony-stimulating Factor Gene Transfer Suppresses Tumorigenicity of a Murine Adenocarcinoma In Vivo. J. Exp. Med., 173: 889-897 (1991).
12. Dranoff, G. et al., Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543 (1993).
13. Fearon, E.r. et al., Interleukin-2 Production by Tumor Cells Bypasses T Helper Function in the Generation of an Anti-tumor Response. Cell, 60: 397-403 (1990).
14. Ferrantini, M. et al., α 1-Interferon Gene Transfer into Metastatic Friend Leukemia Cells Abrogated Tumorigenicity in Immunocompetent Mice: Antitumor Therapy by Means of Inteferon-producing Cells. Cancer Res., 53: 1107-1112 (1993).
15. Golumbek, P. et al., Treatment of Established Renal Cancer by tumor Cells Engineered to Secrete Interleukin-4, Science, 254: 713-716 (1991).
16. Karp, S.E. et al., Cytokine Secretion by Genetically Modified Nonimmunogenic Murine Fibrosarcoma, J. Immunol., 150: 896-908 (1993).
17. Kim et al., Cancer Immunol. Immunother. 1991, 34:163-168.
18. Kim et al., Cancer Research, 1994, 54:2531-2535.

The Applicants hereby notify The Patent Office of the following commonly owned issued patent or co-pending application:

<u>Serial No.</u>	<u>Attorney Docket No.</u>	<u>Filing date</u>	<u>Status</u>
09/016,528	07-894-US	January 30, 1998	U.S. Patent No. 6,187,307
11/909,251	07-895-WO-US	September 20, 2007	Pending
08/242,405	07-896-US	May 13, 1994	U.S. Patent No. 5,759,535

In accordance with MPEP Sections 609 and 707.05(b), it is requested the document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

It is believed that no fee is due in connection with this filing; however, if a fee is due the Commissioner is authorized to charge our deposit account 13-2490.

Respectfully submitted,

Date: October 30, 2007

By: /Y. Elaine Chang/
Yijan Elaine Chang
Reg. No. 54,698
McDonnell, Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive, Suite #3100
Chicago, IL 60606